Equities

Amrutanjan Health Care Ltd

AMRUTANJAN:NSI

Amrutanjan Health Care Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)699.80
  • Today's Change-1.95 / -0.28%
  • Shares traded19.24k
  • 1 Year change+16.25%
  • Beta1.0456
Data delayed at least 15 minutes, as of Nov 22 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Amrutanjan Health Care Ltd grew revenues 10.96% from 3.80bn to 4.21bn while net income improved 12.90% from 398.35m to 449.73m.
Gross margin50.03%
Net profit margin10.86%
Operating margin11.11%
Return on assets12.88%
Return on equity16.98%
Return on investment16.48%
More ▼

Cash flow in INRView more

In 2024, cash reserves at Amrutanjan Health Care Ltd fell by 11.91m. However, the company earned 279.11m from its operations for a Cash Flow Margin of 6.63%. In addition the company generated 191.65m cash from investing, though they paid out 482.66m more in financing than they received.
Cash flow per share18.63
Price/Cash flow per share37.85
Book value per share103.00
Tangible book value per share102.28
More ▼

Balance sheet in INRView more

Amrutanjan Health Care Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 0.74%.
Current ratio4.05
Quick ratio3.62
Total debt/total equity0.0074
Total debt/total capital0.0074
More ▼

Growth rates in INR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 13.70%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)0.66%
Div growth rate (5 year)16.43%
Payout ratio (TTM)21.90%
EPS growth(5 years)12.63
EPS (TTM) vs
TTM 1 year ago
28.86
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.